Trial Profile
A Single-Dose, Open-Label, Extension Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With Irritable Bowel Syndrome With Constipation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2023
Price :
$35
*
At a glance
- Drugs Lovastatin (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Synthetic Biologics; Theriva Biologics
- 23 May 2016 According to a Synthetic Biologics media release, results from this trial were presented at Digestive Disease Week (DDW 2016).
- 23 May 2016 Results published in a Synthetic Biologics media release.
- 05 May 2016 Detailed data will be presented at the Digestive Disease Week 2016, according to a Synthetic Biologics media release.